My research over the last 30 years has evaluated the ability of angiotensin peptides and small molecule Mas agonists to mitigate injury and regenerate injured tissues and product development. Stimulation of Mas through endogenous peptides, analogues and peptidomimetics has been shown to increase stem cells/progenitors in a number of disease states with a deficit regenerative cells and to reduce oxidative stress and inflammation. By targeting these three fundamental processes, a platform leading to clinical development from laboratory observations has led has been generated. Current disease targets include vascular dementia, Alzheimer’s Disease and multiple sclerosis.
Kathleen Rodgers, Ph.D.
Associate Director, Translational Neuroscience, Center for Innovations in Brain Science, Professor, Pharmacology
Contact InformationOffice: 473
- 1984 - Ph.D. - University of California, Riverside (Biomedical Sciences)
Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes.
Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics.
Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer.
A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.
Association Between Specific Type 2 Diabetes Therapies and Risk of Alzheimer's Disease and Related Dementias in Propensity-Score Matched Type 2 Diabetic Patients.